Summary
The macrolide antibiotics erythromycin and triacetyloleandomycin (troleandomycin) are prescribed for many types of infections. As such they are often added to other preexisting drug therapy. Thus, there are frequent opportunities for the interaction of these antibiotics with other drugs.
Both erythromycin and triacetyloleandomycin appear to have the potential to inhibit drug metabolism in the liver and also drug metabolism by micro-organisms in the gut, either through their antibiotic effect or through complex formation and inactivation of microsomal drug oxidising enzymes. Of the two agents, triacetyloleandomycin appears to be the more potent inhibitor of microsomal drug metabolism. Published studies indicate that triacetyloleandomycin can significantly decrease the metabolism of methylprednisolone, theophylline and carbamazepine. Its ability to cause ergotism in patients receiving ergot alkaloids and cholestatic jaundice in patients on oral contraceptives may also be related to its inhibitory effect on drug metabolism.
Erythromycin appears to be a much weaker inhibitor of drug metabolism. There are numerous reports describing apparent interactions of erythromycin with theophylline and a lesser number of reports dealing with carbamazepine, warfarin methylprednisolone and digoxin. There are sufficient data to suggest that erythromycin can, in some individuals, inhibit the elimination of methylprednisolone, theophylline, carbamazepine and warfarin. The mean change in drug clearance is about 20 to 25% in most cases, with some patients having a much larger change than others. Like tetracycline, erythromycin also appears to have the potential for increasing the bioavailability of digoxin in patients who excrete high amounts of reduced digoxin metabolites, apparently through destruction of the gut flora that form these compounds.
Concurrent administration of triacetyloleandomycin with drugs whose metabolism is known to be affected or that could potentially be affected should be avoided unless appropriate adjustments in dosage are made. Coadministration of erythromycin with drugs believed to interact should be undertaken with caution and with appropriate patient monitoring.
Among the other macrolide antibiotics, josamycin has seldom been involved in causing drug interactions, while midecamycin and the older derivative spiramycin have not so far been incriminated.
Similar content being viewed by others
References
Albin, H.; Vinçon, G.; Pehourcq, F. and Dangoumeau, J.: Influence de la josamycine sur la pharmacocinetique de la carbamazepine. Therapie 37: 151–156 (1982).
Bachmann, K.; Schwartz, J.I.; Forney, R.; Frogameni, A. and Jauregui, L.E.: The effect of erythromycin on the disposition kinetics of warfarin. Pharmacology 28: 171–176 (1984).
Bacourt, F. and Couffinhal, J.C.: Ischemic des membres par association dihydroergotamine-triacetyloleandomycin. (Correspondence). Nouvelle Presse Medicale 7: 1956 (1978).
Bartle, W.R.: Possible warfarin-erythromycin interaction. (Correspondence). Archives of Internal Medicine 140: 985–987 (1980).
Belgian Center for Drug Supervision: Levertoxiciteit van troleandomycin en oestrogenen. Folia Pharmaceutica (Brussels) 6: 64 (1979).
Bonfils, C.; Dalet-Beluche, I. and Maurel, P.: Cytochrome P-450 isozyme LM3b from rabbit liver microsomes. Induction of tri-acetyloleandomycin purification and characterization. Journal of Biological Chemistry 258: 5358–5362 (1983).
Bonfils, C.; Dalet-Beluche, I. and Maurel, P.: Induction by tri-acetyloleandomycin and partial purification of a LM3 form of cytochrome P-450 from rabbit liver microsomes. Biochemical and Biophysical Research Communications 104: 1011–1017 (1982).
Branigan, T.A.; Robbins, R.A.; Cady, W.J.; Nickols, J.G. and Ueda, C.T.: The effects of erythromycin on the absorption and disposition of kinetics of theophylline. European Journal of Clinical Pharmacology 21: 115–120 (1981).
Brazier, J.L.; Kofman, J.; Faucon, G.; Perin-Fayolle, M.; Lepape, A. and Lanoue, R.: Retard d’élimination de la theophylline du à la troléandomycine. Absence d’effet de la josamycine. Therapie 35: 545–549 (1980).
Caldwell, J.H. and Cline, C.T.: Biliary excretion of digoxin in man. Clinical Pharmacology and Therapeutics 19: 410–415 (1976).
Claudel, S.; Euvrard, P.; Borx, R.; Chavaillon, A. and Paliard, P.: Cholestase intrahepatique apres association triacetyloleando-mycine-estroprogestatif. Nouvelle Presse Medicale 8: 1182–1183 (1979).
Chang, D.C.; Lauer, B.A.; Bell, T.D. and Chair, H.: Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet 1: 1132–1133 (1978).
Cummins, L.H.; Kozak Jr, P.P. and Gillman, S.A.: Erythromycin’s effect on theophylline blood levels. Correspondence. Pediatrics 59: 144–145 (1977).
Danan, G.; Descatoire, V. and Pessayre, D.: Self-induction of erythromycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450. Journal of Pharmacology and Experimental Therapeutics 218: 509–514 (1981).
DeLaforge, M.; Jaouen, M. and Mansuy, D.: Dual effects of macrolide antibiotics on rat liver cytochrome P-450. Induction and formation of metabolite-complexes. A structure-activity relationship. Biochemical Pharmacology 32: 2309–2318 (1983).
Derrick Jr, C.W. and Reilly, K.M.: Erythromycin, lincomycin, and clindamycin. Pediatric Clinics of North America 30: 63–69 (1983).
Doherty, J.E.: A digoxin-antibiotic drug interaction (Editorial). New England Journal of Medicine 305: 827 (1981).
Dravet, C.; Mesdjian, E.; Cenraud, B. and Roger, J.: Interaction between carbamazepine and triacetyloleandomycin. (Correspondence). Lancet 1: 810–811 (1977).
Fevery, J.; Van Steenbergen, W.; Desmet, V.; Deruyttere, M. and De Groote, J.: Severe intrahepatic cholestasis due to the combined intake of oral contraceptives and triacetyloleandomycin. Acta Clinica Belgica 38: 242–245 (1983).
Fox, J.L.: Infectious asthma treated with triacetyloleandomycin. Pennsylvania Medical Journal 64: 634–635 (1961).
Franco, A.; Boulard, P.; Massot, C.; Lecoeur, J.; Guidicelli, H. and Bessard, G.: Ergotamine par association dihydroergotamine-triacetyloleandomycin. (Correspondence). Nouvelle Presse Medicale 7: 205 (1978).
Fraser, D.G.: Selection of an oral erythromycin product. American Journal of Hospital Pharmacy 37: 1199–1205 (1980).
Frick, P.G.; Riedler, G. and Brogli, H.: Dose response and minimal daily requirement of vitamin K in man. Journal of Applied Physiology 23: 387–389 (1967).
Friedman, H.W. and Bonventre, M.V.: Erythromycin induced digoxin toxicity. (Correspondence). Chest 82: 202 (1982).
Gazzaniga, A.B. and Stewart, D.R.: Possible quinidine-induced hemorrhage in a patient on warfarin sodium. New England Journal of Medicine 280: 711–712 (1969).
Green, J.A. and Clementi, W.A.: Decrease in theophylline clearance after the administration of erythromycin to a patient with obstructive lung disease. Drug Intelligence and Clinical Pharmacy 17: 370–372 (1983).
Gribble, M.J. and Chow, A.W.: Erythromycin. Medical Clinics of North America 66: 79–89 (1982).
Haber, I. and Hubens, H.: Cholestatic jaundice after triacetylol-eandomycin and oral contraceptives. The diagnostic value of gamma-glutamyl transpeptidase. Acta Gastroenterolica Belgica 43: 475–482 (1980).
Hayton, A.: Precipitation of acute ergotism by triacetyloleandomycin. (Correspondence). New Zealand Medical Journal 69: 42 (1969).
Hemsworth, T.C. and Renton, K.W.: Depression of theophylline metabolism and elimination by troleandomycin and erythromycin. Briochemical Pharmacology 30: 1299–1304 (1981).
Hildebrandt, R.; Gundert-Remy, U.; Möller, H. and Weber, E.: Lack of clinically important interaction between erythromycin and theophylline. European Journal of Clinical Pharmacology 26: 485–489 (1984).
Husserl, F.E.: Erythromycin-warfarin interaction. (Correspondence). Archives of Internal Medicine 143: 1831–1836 (1983).
Iliopoulou, A.; Aldhous, M.E.; Johnston, A. and Turner, P.: Pharmacokinetic interaction between theophylline and erylhromycin. British Journal of Clincial Pharmacology 14: 495–499 (1982).
Itkin, I.H. and Menzel, M.L.: The use of macrolide antibiotic substances in the treatment of asthma. Journal of Allergy 45: 146–162 (1970).
Jonkman, J.H.G.; Hendeles, L.; Weinberger, M. and Maddux, M.S.: The theophylline-erythromycin interaction. (Correspondence). Chest 84: 309–312 (1983).
Jusko, W.J.; Schentag, J.J.; Clark, J.H.; Gardner, M. and Yurchak, A.M.: Enhanced biotransformation of theophylline in marijuana and tobacco smokers. Clinical Pharmacology and Therapeutics 24: 406–410 (1978).
Kaplan, M.A. and Godin, M.: The use of triacetyloleandomycin in chronic infectious asthma; in Welch and Marti-Ibanez (Eds). Antibiotics Annual 1958–1959, pp. 273–276 (New York Interscience Publishers, New York 1959).
Kappas, A.; Anderson, K.E.; Conney, A.H. and Alvares, A.P.: Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. Clinical Pharmacology and Therapeutics 20: 643–653 (1977).
Koch-Weser, J.: Quinidine-induced hypoprothrombinemic hemorrhage in patients on chronic warfarin therapy. Annals of Internal Medicine 68: 511–517 (1968).
Kimelblatt, B.J. and Slaughter, R.L.: Lack of effect of intravenous erythromycin lactobionate on theophylline clearance. (Correspondence). Journal of Allergy and Clinical Immunology 65: 313–314 (1980).
Kozak, P.P.; Cummins, L.H. and Gillman, S.H.: Administration of erythromycin to patients on theophylline. (Correspondence). Journal of Allergy and Clinical Immunology 60: 149–151 (1977).
LaForce, C.F.; Miller, M.F. and Chai, H.: Effect of erythromycin on theophylline clearance in asthmatic children. Journal of Pediatrics 99: 153–156 (1981).
LaForce, C.F.; Szefler, S.J.; Miller, M.F.; Ebling, W. and Brenner, M.: Inhibition of methylprednisolone elimination in the presence of erythromycin therapy. Journal of Allergy and Clinical Immunology 72: 34–39 (1983).
Larrey, D.; Funck-Brentano, C.; Briel, P.; Vitaux, J.; Theodore, C.; Babany, G. and Pessayre, D.: Effects of erythromycin on hepatic drug-metabolizing enzymes in humans. Biochemical Pharmacology 32: 1063–1068 (1983a).
Larrey, D.; Tinel, M. and Pessayre, D.: Formation of inactive cytochrome P-450 Fe(11)-metabolite complexes with several erythromycin derivatives but not with josamycin and mide-camycin in rats. Biochemical Pharmacology 32: 1487–1493 (1983b).
Lavarenne, J.; Paire, M. and Talon, O.: Influence d’un nouveau macrolide, la midecamycine sur les taux sanguins de theophylline. Therapie 36: 451–456 (1981).
Le Dafniet, M.; Pessayre, D.; Le Quernec, L. and Erlinger, S.: Effects of troleandomycin administration on cholesterol 7 alpha-hydroxylase activity and bile secretion in rats. Journal of Pharmacology and Experimental Therapeutics 219: 558–562 (1981).
Lesko, L.J.: Nonlinear kinetics and theophylline elimination; in Benet et al. (Eds) Pharmacokinetic Basis for Drug Treatment, pp. 321–332 (Raven Press, New York 1984).
Lindenbaum, J.; Rund, D.G.; Bulter Jr, V.P.; Tse-Eng, D. and Saha, J.N.: Inactivation of digoxin by the gut flora: Reversal by antibiotic therapy. New England Journal of Medicine 305: 789–794 (1981a).
Lindenbaum, J.; Tse-Eng, D.; Bulter Jr, V.P. and Rund, D.G.: Urinary excretion of reduced metabolites of digoxin. American Journal of Medicine 71: 67–74(1981b).
Maddux, M.S.; Leeds, N.H.; Organek, H.W.; Hasegawa, G.R. and Bauman, J.L.: The effect of erythromycin on theophylline pharmacokinetics at steady state. Chest 81: 563–565 (1982).
Mansuy, D.; Delaforge, M.; Le Provost, E.; Flinois, J.P.; Columelli, S. and Beaune, P.: Induction of cytochrome P-450 in rat liver by the antibiotic troleandomycin: Partial purification and properties of cytochrome P-450-troleandomycin metabolite complexes. Biochemical and Biophysical Research Communications 103: 1201–1208 (1981).
Manzo, L.; Gregotti, C.; Richelmi, P.; Di Nucci, A. and Bertie, F.: Effects of phenobarbitone on the distribution metabolism and biliary excretion of erythromycin in rats. Chemotherapy 26: 164–170 (1980).
Matthews, N.T. and Havill, J.H.: Ergotism with therapeutic doses of ergotamine tartrate. New Zealand Medical Journal 89: 476–477 (1979).
May, D.C.; Jarboe, C.H.; Ellenburg, D.T.; Roe, E.J. and Karibo, J.: The effects of erythromycin on theophylline elimination in normal males. Journal of Clinical Pharmacology 22: 125–130 (1982).
McLean, A.J.; McNamara, P.J.; du Souich, P.; Gibaldi, M. and Lalka, D.: Food, splanchic blood flow, and bioavailability of drugs subject to first-pass metabolism. Clinical Pharmacology and Therapeutics 24: 5–10 (1978).
Melethil, S.; Dutta, A.; Ryan, P.B.; Pingleton, S.K. and Kelly, S.J.: Steady state urinary excretion of theophylline and its metabolites in the presence of erythromycin. Research Communications in Chemical Pathology and Pharmacology 35: 341–344 (1982).
Mesdjian, E.; Dravet, C.; Cenraud, B. and Roger, J.: Carbamazepine intoxication due to triacetyloleandomycin administration in epileptic patients. Epilepsia 21: 489–496 (1980).
Miguet, J.P.; Monange, C.; Vuitton, D.; Allemand, H.; Hirsch, J.P.; Carayon, P. and Gisselbrecht, H.: Ictere cholestatique survenu apres administration de triacetyloleandomycine: Interference avec le contraceptifs oraux?. Dix observations. (Correspondence). Nouvelle Presse Medicale 7: 4304 (1978).
Miguet, J.P.; Vuitton, D.; Pessayre, D.; Allemand, H.; Metreau, J.M.; Poupon, R.; Capron, J.P. and Blanc, F.: Jaundice from troleandomycin and oral contraceptives. (Correspondence). Annals of Internal Medicine 92: 434 (1980).
Monks, T.J.; Caldwell, J. and Smith, R.L.: Influence of methylxanthine-conlaining foods on theophylline metabolism and kinetics. Clinical Pharmacology and Therapeutics 26: 513–524 (1979).
Morelli, H.F. and Melmon, K.L.: Drug interactions; in Melmon and Morelli (Eds) Clinical Pharmacology: Basic Principles in Therapeutics, 2nd edition, pp.585–604 (MacMillan, New York 1978).
Murray, M.D. and Brown, B.K.: Theophylline-erythromycin interaction in an infant. Clinical Pharmacy 1: 107–111 (1982).
Parrish, R.A.; Haulman, N.J. and Burns, R.M.: Interaction of theophylline with erythromycin base in a patient with seizure activity. Pediatrics 72: 828–830 (1983).
Pershing, L.K. and Franklin, M.R.: Cytochrome P-450 metabolic-intermediate complex formation and induction by macrolide antibiotics; a new class of agents. Xenobiotica 12: 687–699 (1982).
Pessayre, D.; Descatoire, V.; Konstantinova-Mitcheva, M.; Wandscheer, J.C.; Cobert, B.; Level, R.; Benhamou, P.J.; Jaouen, M. and Mansuy, D.: Self-induction by triacetyloleandomycin of its own transformation into a metabolite forming a stable 456 nm-absorbing complex with cytochrome P-450 Biochemical Pharmacology 30: 553–538 (1981a).
Pessayre, D.; Descatoire, V.; Tinl, M. and Larrey, D.: Self-induction by oleandomycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450. Comparison with troleandomycin. Journal of Pharmacology and Experimental Therapeutics 221: 215–221 1982a).
Pessayre, D.; Larrey, D.; Vitaux, J.; Breil, P.; Belghiti, J. and Benhamou, J.P.: Formation of an inactive cytochrome P-450 Fe(11)-metabolite complex after administration of troleandomycin in humans. Biochemical Pharmacology 31: 1699–1704 (1982b).
Pessayre, D.; Konstantinova-Mitcheva, M.; Descatoire, V.; Cobert, B.; Wandscheer, J.C.; Level, R.; Feldmann, G.; Mansuy, D. and Benhamou, J.P.: Hypoactivity of cytochrome P-450 after triacetyloleandomycin administration. Biochemical Pharmacology 30: 559–564 (1981b).
Pessayre, D.; Tinel, M.; Larrey, D.; Cobert, B.; Funck-Brentano, C. and Babany, G.: Inactivation of cytochrome P-450 by a troleandomycin metabolite. Protective role of glutathione. Journal of Pharmacology and Experimental Therapeutics 224: 685–691 (1983).
Pfeifer, H.J.; Greenblatt, D.J. and Friedman, P.: Effects of three antibiotics on theophylline kinetics. Clinical Pharmacology and Therapeutics 26: 36–40 (1979).
Pingleton, S.K.; Kelly, S.J. and Ryan, P.B.: Lack of effect of erythromycin on theophylline serum levels. (Correspondence). Chest 78: 352 (1980).
Prandota, J.; Tillement, J.P.; d’Athis, P.; Campos, H. and Barre, J.: Binding of erythromycin base to human plasma proteins. Journal of International Medical Research 8 (Suppl. 2): 1–8 (1980).
Prince, R.A.; Wing, D.S.; Weinberger, M.M.; Hendeles, L.S. and Riegelman, S.: Effect of erythromycin on theophylline kinetics. Journal of Allergy and Clinical Immunology 68: 427–431 (1981).
Rall, T.W.: Central nervous system stimulants: The xanthines; in Gillman et al. (Eds) The Pharmacological Basis of Therapeutics, 6th ed., pp. 592–607 (Macmillan, New York 1980).
Reisz, G.; Pingleton, S.K.; Melethil, S. and Ryan, P.B.: The effect of erythromycin on theophylline pharmacokinetics in chronic bronchitis. American Review of Respiratory Diseases 127: 581–584 (1983).
Renton, R.W.; Gray, J.D. and Hall, R.I.: Decreased elimination of theophylline after influenzae vaccination. Canadian Medical Journal 123: 288–290 (1980).
Renton, K.W.; Gray, J.D. and Hung, O.R.: Depression of theophylline elimination by erythromycin. Clinical Pharmacology and Therapeutics 30: 422–426 (1981).
Richer, C.; Mathieu, M.; Bah, H.; Thuillex, C.; Duroux, P. and Giudicelli, J.F.: Theophylline kinetics and ventilatory flow in bronchial asthma and chronic airflow obstruction. Influence of erythromycin. Clinical Pharmacology and Therapeutics 31: 579–586 (1982).
Rollux, R.; Plottin, F.; Mingat, J. and Bessard, G.: Ictere apres association estroprogestatif-troleandomycine, trois observations. Nouvelle Presse Medicale 8: 1694 (1979).
Ruff, F.; Santais, M.C.; Chastagnol, D.; Huchon, G. and Durieux, P.: Macrolide et theophylline: Absence d’interaction josamycin-theophylline. Nouvelle Presse Medicale 10: 175 (1981).
Spector, S.L.; Katz, F.H. and Farr, R.S.: Troleandomycin: Effectiveness in steroid-dependent asthma and bronchitis. Journal of Allergy and Clinical Immunology 54: 367–379 (1974).
Stratton, M.A.: Theophylline-erythromycin base interaction. Case report and kinetic profile. Clinical Pharmacy 2: 183–186 (1983).
Straughan, J.: Erythromycin-carbamazepine interaction? (Correspondence). South African Medical Journal 61: 420–421 (1982).
Stults, B.M.; Felice-Johnson, J.; Higbee, M.D. and Hardigan, K.: Effect of erythromycin stearate on serum theophylline concentration in patients with chronic obstructive lung disease. Southern Medical Journal 76: 714–718 (1983).
Szefler, S.J.; Brenner, M.; Jusko, W.J.; Spector, S.L.; Flesher, K.A. and Ellis, E.F.: Dose- and time-related effect of troleandomycin on methylprednisolone elimination. Clinical Pharmacology and Therapeutics 32: 166–171 (1982a).
Szefler, S.J.; Ellis, E.F.; Brenner, M.; Rose, J.Q.; Spector, S.L.; Yurchak, A.M.; Andrews, F. and Jusko, W.J.: Steroid-specific and anticonvulsant interaction aspects of troleandomycinsteroid therapy. Journal of Allergy and Clinical Immunology 69: 455–460 (1982b).
Szefler, S.J.; Rose, J.Q.; Ellis, E.F.; Spector, S.L.; Green, A.W. and Jusko, W.J.: The effect of troleandomycin on methylprednisolone elimination. Journal of Allergy and Clinical Immunology 66: 447–451 (1980).
Tang-Liu, D.D.; Williams, R.L. and Riegelman, S.: Nonlinear theophylline elimination. Clinical Pharmacology and Therapeutics 31: 358–369 (1982).
Tardrew, P.L.; Mao, J.C.H. and Kenney, D.: Antibacterial activity of 2′-esters of erythromycin. Applied Microbiology 18: 159–165 (1969).
Upton, R.A.; Thiercelin, J.-F.; Moore, J.K. and Riegelman, S.: A method for estimating within-individual variability in clearance and in volume ot distribution from standard bioavailability studies. Journal of Pharmacokinetics and Biopharmaceutics 10: 135–146 (1982).
Weinberger, M.: Interaction between erythromycin and theophylline. (Correspondence). Pediatrics 61: 324–325 (1978a).
Weinberger, M.: TAO and theophylline. (Correspondence). Hospital Practice 13: 22 (1978b).
Weinberger, M.; Hudgel, D.; Spector. S. and Chidsey, C.: Inhibition of theophylline clearance by troleandomycin. Journal of Allergy and Clinical Immunology 59: 228–231 (1977).
Welling, P.G.: Influence of food and diet on gastrointestinal drug absorption: A review. Journal of Pharmacokinetics and Biopharmaceutics 5: 291–334 (1977).
Wilkinson, G.R. and Shand, D.G.: A physiological approach to hepatic drug clearance. Clinical Pharmacology and Therapeutics 18: 377–390 (1975).
Wong. Y.Y.; Ludden, T.M. and Bell, R.D.: Effect of erythromycin on carbamazepine kinetics. Clinical Pharmacology and Therapeutics 33: 460–464 (1983).
Zarowitz. B.J.; Szefler, S.J. and Lasezkay, G.M.: Effect of erythromycin base on theophylline kinetics. Clinical Pharmacology and Therapeutics 29: 601–605 (1981).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ludden, T.M. Pharmacokinetic Interactions of the Macrolide Antibiotics. Clin Pharmacokinet 10, 63–79 (1985). https://doi.org/10.2165/00003088-198510010-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-198510010-00003